ArticleExperimental neurology2010
Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.
Article in Experimental neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Pesticide exposure and neurodevelopmental outcomes: review of the epidemiologic and animal studies.Journal of toxicology and environmental health. Part B, Critical reviews · 2013Pooled it
- Primary prevention of Parkinson's disease: proceedings, the 8C's and a position statement from the Parkinson's disease prevention think tank.NPJ Parkinson's disease · 2026Review
- Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.BMC neuroscience · 2025Article
- Neuroprotective Agents: Implications for Parkinson's Disease Treatment.Current Alzheimer research · 2025Review
- Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort.Neurology · 2024Article
- Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.Research square · 2024Article
- Caffeine plus haloperidol reduces fatigue in an experimental model of Parkinson's disease - a prospective to APurinergic signalling · 2024Article
- Prevention of Parkinson's Disease: From Risk Factors to Early Interventions.CNS & neurological disorders drug targets · 2024Review
- Association of coffee consumption and striatal volume in patients with Parkinson's disease and healthy controls.CNS neuroscience & therapeutics · 2023Article
- Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson's disease patients and healthy controls.BMC medicine · 2023Article
- Review
- Neuroprotective Effects of Coffee Bioactive Compounds: A Review.International journal of molecular sciences · 2020Review
- Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration.International journal of molecular sciences · 2020Review
- Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.International journal of molecular sciences · 2020Review
- Neuroprotection in Parkinson's disease: facts and hopes.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- AnIBRO reports · 2019Article
- The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease.Translational neurodegeneration · 2019Review
- Caffeine, creatine, GRIN2A and Parkinson's disease progression.Journal of the neurological sciences · 2017Article
- Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice.Neurobiology of aging · 2017Article
- Role of cytochrome c in α-synuclein radical formation: implications of α-synuclein in neuronal death in Maneb- and paraquat-induced model of Parkinson's disease.Molecular neurodegeneration · 2016Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Environmental exposures suspected of contributing to the pathophysiology of Parkinson's disease (PD) include potentially neurotoxic pesticides, which have been linked to an increased risk of PD. Conversely, possible protective factors such as the adenosine antagonist caffeine have been linked to a reduced risk of the disease. Here we assessed whether caffeine alters dopaminergic neuron loss induced by exposure to environmentally relevant pesticides (paraquat and maneb) over 8weeks. The number of nigral neurons positive for tyrosine hydroxylase immunoreactivity (TH+) was assessed using stereological methods and found to be significantly reduced (to 60% of control) by combined pesticide treatment. Caffeine at 20mg/kg significantly reduced TH+ neuron loss (to 85% of the respective control). The results demonstrate the neuroprotective potential of caffeine in a chronic pesticide exposure model of model of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.